Investor Relations

2016 News Releases

Webcast ImageWebcast
KemPharm Inc at the Oppenheimer & Co. 27th Annual Healthcare Conference (Replay)
03/21/17 at 9:45 a.m. ET
KemPharm Inc at the Oppenheimer & Co. 27th Annual Healthcare Conference
Tuesday, March 21, 2017 9:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/20/16KemPharm Granted "Fast Track" Designation for KP201/IR
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa, Dec. 20, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its Investigational New Drug application for KP201/IR has been granted “Fast Track” designation by the U.S. Food and Drug Administration (FDA). KP2... 
Printer Friendly Version
12/14/16KemPharm’s KP415, An Investigational Prodrug of D-Methylphenidate, Completes Phase 1 Proof-of-Concept Trial for the Treatment of ADHD
  Both Early and Extended Release of the Methylphenidate Prodrug was observed in the KP415.101 Study Conference Call and Live Audio Webcast with Dr. Scott Kollins Scheduled for Today at 4:30 p.m., ET CORALVILLE, Iowa, Dec. 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the results of its Phase 1 proof-of-concept clinical trial of KP415, KemPhar... 
Printer Friendly Version
11/29/16KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its Investigational New Drug (IND) application for KP201/IR has been accepted by the U.S. Food and Drug Administration (FDA). KP201/IR, KemPharm’s ... 
Printer Friendly Version
11/09/16KemPharm, Inc. Reports Third Quarter 2016 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 5:00 p.m., ET Recent Clinical Development & Regulatory Highlights: Prioritized KP415 and KP201/IR as co-lead product candidates Received clearance from the U.S. Food and Drug Administration (FDA) to initiate clinical program for KP415 Filed Investigational New Drug (IND) application with FDA for KP201/IR Initiated Formal Dispute Resolution Request (FDRR) Process with the FDA for Apadaz™ ... 
Printer Friendly Version
11/03/16KemPharm Appeals FDA Complete Response Letter on Apadaz™ by Initiating a Formal Dispute Resolution Process
CORALVILLE, Iowa, Nov. 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has appealed the Food and Drug Administration's (FDA) Complete Response Letter (CRL) for Apadaz™ (benzhydrocodone and acetaminophen) through the initiation of the Formal Dispute Resolution Request (FDRR) process.  Apadaz™ is KemPharm’s investigational product candidate that is int... 
Printer Friendly Version
11/01/16KemPharm, Inc. to Report Third Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for November 9th, 2016, 5:00 p.m. ET CORALVILLE, Iowa, Nov. 01, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, November 9, 2016, at 5:00 p.m. ET, to discuss its corporate and financial results for the third quarter 2016. Co... 
Printer Friendly Version
10/25/16KemPharm Files IND for KP201/IR, a Single-Entity Benzhydrocodone HCl Immediate Release Abuse-Deterrent Prodrug for the Treatment of Acute Pain
KP201/IR could be the first single entity (APAP-free), IR hydrocodone product for pain analgesia with abuse-deterrent properties CORALVILLE, Iowa, Oct. 25, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin human clinical trials of KP201... 
Printer Friendly Version
10/18/16KemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology
Agreement focused on KemPharm's current and in-development IR Opioid Pipeline CORALVILLE, Iowa and PALATINE, Ill., Oct. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) today announced that they have entered into a License Agreement (the "Agreement") whereby Acura will provide its proprietary Aversion® Technology to KemPhar... 
Printer Friendly Version
10/11/16KemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD
KP415, KemPharm’s co-lead product candidate, is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa, Oct. 11, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its Investigational New Drug (IND) application for KP415 has been accepted by the U.S. Food and Drug Administration (FDA). KP415, KemPharm’s co-lead prod... 
Printer Friendly Version
09/19/16KemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate
KP415 is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa, Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin human clinical trials of KP415, the Company’s prodrug, extended release (E... 
Printer Friendly Version
09/15/16KemPharm, Inc. Provides Corporate and Clinical Update
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET KemPharm adjusts product development timelines following full pipeline analysis and positions KP415 and KP201/IR as lead product candidates to capitalize on favorable developmental, regulatory and market conditions Announces intent to begin the Formal Dispute Resolution regulatory process with the FDA for Apadaz™ Defers commercial program for Apadaz CORALVILLE, Iowa, Sept. 15, 2016 (GLOBE NEWSWIR... 
Printer Friendly Version
09/08/16KemPharm to Present Data at PAINWeek 2016
Poster Presentations to Highlight Tamper and Intranasal Abuse Resistance Studies Involving KemPharm’s Prodrug of Hydrocodone CORALVILLE, Iowa, Sept. 08, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it will present data from two studies involving KP201, the company’s prodrug of hydrocodone (benzhydrocodone), at the PAINWeek 2016 Annual Meeting, September... 
Printer Friendly Version
08/10/16KemPharm, Inc. Reports Second Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET Recent Clinical Development & Regulatory Highlights: Completed FDA End of Review meeting for Apadaz™ following receipt of Complete Response Letter Reported results from KP511 Phase 1 Proof-of-Concept Trial; Announces plans to initiate human abuse liability program for KP511 before year-end Completed key FDA regulatory milestones for KP415 and KP201/IR Recent Corporate and Financial Highlights: Ho... 
Printer Friendly Version
08/02/16KemPharm, Inc. to Report Second Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for August 10, 2016, 8:30 a.m. ET CORALVILLE, Iowa, Aug. 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 10, 2016, at 8:30 a.m. ET, to discuss its corporate and financial results for the second quarter 2016. Confe... 
Printer Friendly Version
07/28/16KemPharm to Present at Canaccord Genuity 36th Annual Growth Conference
CORALVILLE, Iowa, July 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 36th Annual Growth Conference being held August 10-11, 2016, at the InterContinental Boston Hotel. Details of KemPharm's presentation are as follows: Date: Thursday, Au... 
Printer Friendly Version
07/14/16KemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415
KemPharm expects to file INDs for both product candidates during second half of 2016 CORALVILLE, Iowa, July 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  today announced the completion of milestone meetings with the U.S. Food and Drug Administration (FDA) for KP201/IR, the company’s single-entity, benzhydrocodone HCl immediate-release, abuse-deterrent product candi... 
Printer Friendly Version
06/28/16KemPharm’s Prodrug of Hydromorphone, KP511, Demonstrates Comparable Oral Pharmacokinetics to Hydromorphone in Phase 1 Trial
KP511 clinical data consistent with preclinical animal data CORALVILLE, Iowa, June 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced results from a Phase 1 proof-of-concept trial (KP511.101) with KP511, KemPharm’s prodrug of hydromorphone.  In the trial, KemPharm observed comparable hydromorphone exposure between 4 mg DilaudidTM Oral Liquid and an equimo... 
Printer Friendly Version
06/13/16FDA Issues Complete Response Letter for Apadaz™ New Drug Application
CORALVILLE, Iowa, June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for Apadaz™ (benzhydrocodone and acetaminophen), KemPharm’s investigational abuse-deterrent product candidate for the short-term management of acute p... 
Printer Friendly Version
06/09/16KemPharm Files NDA Amendment Request with FDA for Apadaz™
Discussions On-going with FDA on Potential Apadaz Product Labeling CORALVILLE, Iowa, June 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has filed with the U.S. Food and Drug Administration (FDA) an amendment request to its New Drug Application (NDA) for Apadaz™ (benzhydrocodone hydrochloride and acetaminophen), KemPharm’s investigational abus... 
Printer Friendly Version
06/06/16KemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids
CORALVILLE, Iowa, June 06, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will present data from a study (KP201.A03) evaluating the pharmacokinetics and intranasal abuse potential of benzhydrocodone hydrochloride (HCI) (also known as KP201) at the 2016 International Conference on Opioids (ICOO) in Boston, MA.  KP201 is a prodrug formed by a covalen... 
Printer Friendly Version
05/18/16KemPharm, Inc. to Host Annual Meeting of Stockholders on Tuesday, May 24, 2016 at 9:00 a.m. ET
CORALVILLE, Iowa, May 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that KemPharm will host its annual meeting of stockholders on Tuesday, May 24, 2016, at 9:00 a.m. ET at the Harvard Club of New York City. Information for KemPharm, Inc.’s Annual Meeting of Stockholders:     Date:   Tuesday, May 24, 2016 ... 
Printer Friendly Version
05/12/16KemPharm, Inc. Reports First Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights: Introduced Apadaz™ as the proprietary name for KP201/APAP FDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against inclusion of abuse deterrent labeling Granted “Fast Track” designation for, and received clearance from FDA to initiate human clinical trials, of KP511, KemPharm’s prodrug of hydromorphone R... 
Printer Friendly Version
05/10/16KemPharm Receives “Fast Track” Designation for KP511, an Investigational Prodrug of Hydromorphone
KemPharm developing KP511 as an abuse-deterrent, extended-release product candidate – KP511/ER CORALVILLE, Iowa, May 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that KP511, KemPharm’s prodrug of hydromorphone, has been granted “Fast Track” designation by the U.S. Food and Drug Administration (FDA).  KP511 is being developed as an abuse-deterrent, e... 
Printer Friendly Version
05/05/16Statement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz™
CORALVILLE, Iowa, May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) reviewed and voted on Apadaz™ (benzhydrocodone hydrochloride and acetaminophen), KemPharm’s investigational abus... 
Printer Friendly Version
05/05/16FDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™
Trading of KMPH Common Stock Halted KemPharm Conference Call Today at 6:15 p.m. ET CORALVILLE, Iowa, May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that NASDAQ halted trading of KemPharm’s common stock this morning.  The Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. ... 
Printer Friendly Version
05/03/16KemPharm, Inc. to Report First Quarter 2016 Results
Conference Call and Live Audio Webcast Scheduled for May 12, 2016, 4:30 p.m. ET CORALVILLE, Iowa, May 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will host a conference call and live audio webcast on Thursday, May 12, 2016, at 4:30 p.m., ET to discuss its corporate progress and financial results for the first quarter 2016. Confe... 
Printer Friendly Version
04/19/16KemPharm Announces New Additions to Senior Leadership Team
Daniel L. Cohen, global public policy and government relations leader, appointed Executive Vice President, Government and Public Relations Rene A. Braeckman, Ph.D., clinical development expert, appointed Vice President, Clinical Development CORALVILLE, Iowa, April 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced the addition of two new members to its... 
Printer Friendly Version
04/05/16KemPharm to Present at the Needham & Company’s 15th Annual Healthcare Conference in New York, NY
CORALVILLE, Iowa, April 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Needham & Company’s 15th Annual Healthcare Conference being held in New York, NY, April 12 - 13, 2016. Details of KemPharm's presentation are as follows: Date:             Tuesday, A... 
Printer Friendly Version
03/28/16KemPharm Receives Clearance from FDA to Initiate Human Clinical Trials of KP511, an Investigational Prodrug of Hydromorphone
KemPharm plans to develop KP511 as an abuse-deterrent, extended-release product CORALVILLE, Iowa, March 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that its Investigational New Drug (IND) application for KP511, KemPharm’s prodrug of hydromorphone, has been accepted by the U.S. Food and Drug Administration (FDA).  KP511 is being developed as an abuse-deterrent, extended-release (ER) prodrug for the management of pain severe enough to require daily, around-the-cloc... 
Printer Friendly Version
03/24/16KemPharm Receives NDA User Fee Waiver from FDA
CORALVILLE, Iowa, March 24, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration (FDA) has granted a fee waiver and has refunded the full user fee amount of $2,374,200 for its New Drug Application (NDA) filing for KP201/APAP, the Company’s investigational immediate release combination of its hydrocodone prodrug, KP201 (... 
Printer Friendly Version
03/14/16KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP
CORALVILLE, Iowa, March 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for May 5, 2016, to review KemPharm’s New Drug Application (NDA) for KP201/APAP, its lead investigational drug candidate for the short-term management of acute pain. KP201/APAP is a combinat... 
Printer Friendly Version
03/10/16KemPharm, Inc. Reports Q4 and Year End 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights: Submitted New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the U.S. Food and Drug Administration (FDA) Granted priority review by the FDA for the KP201/APAP NDA, with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 9, 2016 Filed Investigational New Drug (IND) a... 
Printer Friendly Version
03/07/16KemPharm Files IND for KP511, an Investigational Prodrug of Hydromorphone
CORALVILLE, Iowa, March 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) requesting clearance to begin human clinical trials of KP511, KemPharm’s prodrug of hydromorphone.  KemPharm plans to develop KP511 as an abuse-deterrent, ER medication for the treatment of moderate to severe pain. Similar to KemPharm’s lead product candidate, KP201/APAP, which is cu... 
Printer Friendly Version
03/02/16KemPharm, Inc. to Report Fourth Quarter and Year End 2015 Results
Conference Call and Live Audio Webcast Scheduled for March 10, 2016, 4:30 p.m. ET CORALVILLE, Iowa, March 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the Company will host a conference call and live audio webcast on Thursday, March 10, 2016, at 4:30 p.m. ET, to discuss its corporate and financial results for the fourth quarter and year end 201... 
Printer Friendly Version
02/19/16KemPharm to Present Data From Oral Human Abuse Liability Study for Investigational Drug KP201/APAP at the 2016 AAPM Annual Meeting
CORALVILLE, Iowa, Feb. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced that it will present data from an oral human abuse liability, pharmacokinetic and safety study (KP201.A01) of KP201/APAP, today at the 32nd Annual Meeting of the American Academy of Pain Medicine (AAPM) in Palm Springs, CA. KP201/APAP is an immediate release combination of KP201, KemPharm's prodrug of hydrocodone and acetaminophen (APAP) which is being developed as an abuse-deterrent immediate release pr... 
Printer Friendly Version
02/18/16KemPharm, Inc. to Present at Upcoming Investor Conferences
CORALVILLE, Iowa, Feb. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the RBC Capital Markets 2016 Healthcare Conference being held in New York, NY, February 23-24, 2016. Dr. Mickle will also present at the Cowen & Co. 36th Annual Health Care Conference 2016 be... 
Printer Friendly Version
02/10/16FDA Grants Priority Review to KemPharm for KP201/APAP NDA
If Approved, KP201/APAP Could Become the First Immediate-Release Hydrocodone Combination Product With Abuse-Deterrent Properties CORALVILLE, Iowa, Feb. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that the New Drug Application (NDA) for KP201/APAP, its investigational drug candidate for the short-term management of acute pain, has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA).  In addition, the FDA has set a target action... 
Printer Friendly Version
02/09/16KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
CORALVILLE, Iowa, Feb. 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the closing of $86.25 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), which includes the exercise in full by the initial purchasers of their option to purchase up to an additional $11.25 million aggregate prin... 
Printer Friendly Version
02/04/16KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
CORALVILLE, Iowa, Feb. 04, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH)  announced today the pricing of $75.0 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, KemPharm also granted the initial purchasers of the notes a 30-day option to purchase up to an additional ... 
Printer Friendly Version
01/07/16KemPharm Added to NASDAQ Biotechnology Index
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective December 21, 2015. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either biotechnology or pharmace... 
Printer Friendly Version